Korsana Biosciences, Inc.
KRSA · XNASCIK 1755237fmd_00Y7FQ5VR2JYT4TSVBV2YQMBMAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 5 | 2 | 4 | 0 | 0 | 2 | 2 |
| Research and development | 88 | 95 | 56 | 38 | 6 | 2 | 0 | 1 |
| Total operating expenses | 115 | 130 | 84 | 59 | 19 | 13 | 6 | 7 |
| Operating income | (115) | (125) | (81) | (55) | (19) | (13) | (4) | (5) |
| Other non-operating income (expense) | – | – | 1 | (0) | 0 | 0 | 1 | 1 |
| Income before taxes | (115) | (122) | (122) | (52) | (44) | (5) | (3) | (4) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (115) | (122) | (122) | (52) | (18) | (13) | (3) | (4) |
| Net income | (115) | (123) | (78) | (52) | (44) | (5) | (3) | (4) |